Parisa Shamsesfandabadi | Radiation oncology | Best Researcher Award

Dr. Parisa Shamsesfandabadi | Radiation oncology | Best Researcher Award

Dr. Parisa Shamsesfandabadi 🇺🇸 is a passionate radiation oncologist with a dynamic academic and clinical background, currently serving as Chief Resident at Allegheny Health Network in Pittsburgh, PA 💼. She combines a global medical foundation from Iran with extensive U.S. clinical training 🇮🇷➡️🇺🇸. Driven by innovation and compassion, Parisa has earned national recognition with multiple prestigious awards 🏅. Her dedication extends beyond clinical excellence to impactful research, global health, and mentorship 🌍📚. With hands-on experiences at leading institutions like Duke, UNC, and VA Medical Center, her expertise spans brain, breast, liver, and prostate cancer research 🧠💪. Parisa’s unique blend of research, service, and leadership reflects her lifelong commitment to patient care, academic excellence, and transformative cancer therapy 🌟. In addition to her clinical role, she actively contributes as an editorial assistant, social ambassador, and peer-reviewer to renowned medical journals and organizations 📖🤝. She’s a true rising star in oncology 🚀.

Profile

Education 🎓

📍 Chief Resident, Radiation Oncology – Allegheny Health Network, PA (2024–Present) 👩‍⚕️
📍 Residency, Radiation Oncology – Allegheny Health Network, PA (2019–2024) 💉
📍 Internship (PGY-1), Transitional Year – Southern Hills Hospital, Las Vegas, NV (2019–2020) 🏥
📍 M.D. – Kashan University of Medical Sciences, Iran (2007–2014) 🎓🇮🇷
📍 High School – Tehran Farzanegan School, NODET (2000–2007) 🧠🏫
Parisa’s academic journey reflects brilliance from the start, attending Iran’s elite NODET school 🌟. She pursued medicine at KaUMS, consistently ranking top in medical Olympiads 🥇. Her U.S. medical training includes internship and residency in highly reputed institutions, leading to her current leadership as Chief Resident 🧑‍⚕️. Her academic record is peppered with awards, research, and international training, preparing her for a successful future as a physician-scientist and leader in cancer care 🧬🩺.

Experience 👨‍🏫

📍 Chief Resident, Radiation Oncology – AHN (2024–Present)
📍 Research Associate – VA Medical Center, Durham, NC 🧪
📍 Visiting Scholar – Duke, UNC, CCC Las Vegas 🏫
📍 Research Visitor – RAI Lab, Duke University (Glioma Imaging) 🧠
📍 Research Associate – KaUMS, Iran (Probiotics Study) 🧃
📍 Medical Assistant – Advanced Pain Management, NV 💊
📍 Volunteer – Rural Clinics, Pediatrics & Geriatrics Programs 🧒👵
📍 Editorial Assistant – eContour 📘
📍 Communications Intern – RTOG Foundation 💬
Dr. Parisa brings a rich portfolio of clinical and research experience across top U.S. and international institutions 🌍. From clinical research on prostate and brain cancers to hands-on patient care and administrative duties, she is known for her leadership, empathy, and academic dedication 🏥🧠📊.

Awards & Recognitions 🏅

🎖 2024 RTOG Communications Intern
💰 2023 $25K Grant – MRLinac Sarcoma (Benedum Foundation)
🧳 2023 Travel Grants – ARS, ACRO, ACR
🥇 2022 Resident Best Abstract – ABS
🎖 2022 Editorial/Fellow Roles – eContour, The Mednet, NRG
🌟 2022 RePRT Peer Reviewer – Red Journal
🏆 2022 Travel Award – eContour Vulvar Cancer Guidelines
👩‍🎓 Olympiad Champion – 4x Gold in Iran Medical Olympiads
🧠 UNESCO Youth Award – Earthquake Awareness Project
🏅 Sharif University Medal – Math & Graphs Competition
🧪 Ranked 1st in Nationwide Chemistry Lab Exam
📕 Published Short Book – “World of Animals”
📚 Parisa’s excellence is recognized through national and international grants, editorial roles, peer-review selections, and top medical student honors 🏅. From early academic brilliance to clinical and research impact, her accolades reflect a rare blend of intellect, service, and innovation 🌍✨.

Research Interests 🔬

🧠 Radiogenomics – Brain Cancer Imaging (Duke, UNC)
🧬 MR-Linac SBRT – Liver, Pancreatic, Prostate, and Breast Cancers
💪 Strength Training Impact – Radiotherapy in Breast Cancer
🧲 Adaptive Radiation Therapy – CBCT, MRI-based Comparisons
🔍 Treatment Planning – Monte Carlo vs Cone Algorithm
🧫 Biomarker Evaluation – Breast Cancer (KaUMS & Leiden University)
🧃 Probiotics vs Regular Yogurt in Pediatric Diarrhea
🖥 Editorial & Peer Review Roles – Red Journal, The Mednet, eContour
Dr. Shamsesfandabadi’s research bridges advanced imaging, functional planning, and personalized therapy in oncology 🧠. Her projects focus on enhancing precision radiation therapy using radiogenomics, AI-driven adaptive planning, and improving survivorship through integrative approaches 💻💡. She’s driven to optimize outcomes in patients with complex cancers like gliomas, HCC, and pancreatic malignancies, while actively contributing to guidelines and clinical trials 🧪💥. A rising voice in the next-gen of physician-scientists 🌟.

Publications 
  • -Kirichenko, A., Uemura, T., Hasan, S., Lian, Y., Abel, S., Renz, P.,
    Shamsesfandabadi, P., Carpenter, J., Thai, N., “Stereotactic Body Radiotherapy
    (SBRT) for Hepatocellular Carcinoma (HCC) with Single Photon Emission
    Computed Tomography (SPECT) Functional Treatment Planning in Patients with
    Advanced Hepatic Cirrhosis.” Advances in Radiation Oncology (Accepted,
    July 2023).
  • Goss, M., Champ, C., Trombetta, M, Shamsesfandabadi, P., DeMartino, V.,
    Wegner, R., Beriwal, S., Eisen, V. “The Comparison of Collapsed Cone and
    Monte Carlo Algorithms in Tangential Breast Planning.” Journal of Radiotherapy
    in Practice. (April 2023).
  • Mazurowski, M.A., Clark, K., Czarnek, N. M., Shamsesfandabadi, P., et al.
    “Radiogenomics of lower-grade glioma: algorithmically assessed tumor shape
    is associated with tumor genomic subtypes in a multi-institutional study with
    The Cancer Genome Atlas data.” Journal of Neuro-Oncology. 2017, May;
    133(1): 27-35. Cited in PubMed; PMID: 28470431.
  • Mazurowski, M. A., Clark, K., Czarnek, N. M., Shamsesfandabadi, P., et al.
    (2017, March 21). “Radiogenomic analysis of lower grade glioma: a pilot multiinstitutional study shows an association between quantitative image features
    and tumor genomics.” SPIE, The international society for optics and photonics.
  • – Sharif, A., Kheirkhah, D., Shamsesfandabadi, P., et al. “Comparison of Regular
    and Probiotic Yogurts in Treatment of Acute Watery Diarrhea in Children.”
    Journal of Probiotics and Health. 2016, Feb; 5(1): 164.

Pedram Fadavi | Radiation oncology | Best Researcher Award

Dr. Pedram Fadavi | Radiation oncology | Best Researcher Award

Dr. Pedram Fadavi, M.D., is a distinguished radiation oncologist and associate professor at Iran University of Medical Sciences (IUMS). Born in Tehran, Iran (1974), he specializes in cancer treatment, radiotherapy, and oncological research. With over two decades of experience, he has contributed extensively to academia and clinical practice. His expertise spans breast, head, neck, and gynecologic cancers. He has published influential research in radiomics, chemotherapy delays, and treatment-induced complications. A dedicated educator, he mentors medical students and residents while advancing oncology research. 📚💡

Profile

Education 🎓

Dr. Fadavi earned his M.D. (2000) and board certification in Radiation Oncology (2006) from Shahid Beheshti University, Tehran. He completed a seven-year medical program (1993-2000) and specialized in radiation oncology during his residency (2002-2006). He holds an Iran Medical Council license (No. 76602) and actively contributes to medical education and research at IUMS. His training provided a strong foundation in oncologic treatments and innovative radiotherapy techniques. 🔬📖

Experience 👨‍🏫

Since 2006, Dr. Fadavi has served as a radiation oncologist at Haftome Tir Hospital (IUMS). He became an associate professor in 2008, teaching at IUMS and Tehran University of Medical Sciences (2011-2013). His clinical expertise includes radiotherapy advancements, cancer management, and interdisciplinary oncology research. He has led multiple projects addressing radiation-induced complications and patient outcomes. His leadership in academic and clinical oncology has shaped the future of radiation therapy in Iran. 🌍🔬

Research Interests 🔬

Dr. Fadavi’s research centers on radiomics, predictive modeling, and improving radiotherapy outcomes. His recent studies explore machine learning applications in radiation toxicity prediction, chemotherapy delays, and novel treatment strategies for breast, cervical, and head-and-neck cancers. He investigates biomarkers for cancer prognosis and response to therapy, with a strong emphasis on precision oncology. His work in computational oncology and artificial intelligence-driven diagnostics is shaping the future of personalized cancer treatment. 💻🧬Awards & Recognitions 🏅

Dr. Fadavi has received numerous accolades for his contributions to radiation oncology and medical research. His work on radiomics, treatment toxicity, and innovative oncological therapies has been recognized in national and international forums. His publications in leading journals and collaborations with top researchers underscore his impact on global cancer research. He has also been honored for his excellence in medical education, research innovation, and commitment to improving patient care. 📜🏅

Publications 📚

Nuo Yu | Radiomics | Best Researcher Award

Ms. Nuo Yu | Radiomics | Best Researcher Award

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College ,China

Nuo Yu is a Ph.D. candidate at the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences, specializing in radiation oncology with a focus on esophageal squamous cell carcinoma (ESCC). His research primarily explores innovative chemoradiotherapy regimens to improve treatment outcomes for patients with locally advanced ESCC.

Yu has contributed to several peer-reviewed publications in SCI-indexed journals. Notably, he co-authored a study titled “Conversion Chemoradiotherapy Combined with Nab-Paclitaxel Plus Cisplatin in Patients with Locally Advanced Borderline-Resectable or Unresectable Esophageal Squamous Cell Carcinoma: A Phase I/II Prospective Cohort Study,” published in Strahlentherapie und Onkologie in August 2024. This research evaluated the efficacy and safety of a novel chemoradiotherapy regimen, demonstrating promising results in locoregional control and overall survival rates.

In March 2023, Yu co-authored another significant study, “Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study,” published in Current Cancer Drug Targets. This research focused on treatment strategies for elderly patients with ESCC, highlighting the potential benefits of combining chemoradiotherapy with nimotuzumab.

Yu’s work has been recognized at international conferences, including presentations at the American Society for Radiation Oncology (ASTRO), the Federation of Asian Organizations for Radiation Oncology (FARO), and the Korean Society for Radiation Oncology (KOSRO). These engagements underscore his active participation in the global radiation oncology community and his commitment to advancing cancer treatment research.

While still in the early stages of his career, Yu’s focused research on ESCC and his contributions to the field of radiation oncology position him as a promising candidate for the Best Researcher Award. Continued efforts to expand his research scope, increase publication impact, and assume leadership roles in larger-scale studies will further strengthen his candidacy.

Profile

Scientific Publications